Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Preclinical characterisation of 111In‐DTPA‐trastuzumab

Open access
Lub‐de Hooge, Marjolijn N, Kosterink, Jos G W, Perik, Patrick J, Nijnuis, Hugo, Tran, Ly, Bart, Joost, Suurmeijer, Albert J H, de Jong, Steven, Jager, Pieter L, de Vries, Elisabeth G E·2004·British Journal of Pharmacology

Abstract

Trastuzumab (Herceptin®) is a recombinant humanised IgG1 monoclonal antibody against the human epidermal growth factor receptor 2 (HER2), used for metastatic breast cancer treatment. Radiolabelled trastuzumab may have several future applications for diagnostic use. The aim of the present study was to develop clinical grade 111 Indium (111 In) radiolabelled trastuzumab, to evaluate the stability and immunoreactivity of the tracer and to perform a biodistribution study in human tumour‐bearing mice. Trastuzumab was radiolabelled with 111 In using DTPA as a chelator. 111 In‐DTPA‐trastuzumab (labelling yield 92.3±2.3%, radiochemical purity 97.0±1.5%) is stable in PBS when stored at 4°C for more than 14 days. The immunoreactive fraction determined by cell‐binding assays, using the HER2‐overexpressing human ovarian SK‐OV‐3 tumour cell line, was 0.87±0.06. Biodistribution and tumour targeting were studied in HER2 receptor‐positive and ‐negative tumour‐bearing athymic mice. The HER2‐positive tumour showed (9.77±1.14% injected dose per gram (ID g−1)) substantial uptake of the labelled antibody already after 5 h. The difference in uptake between HER2‐positive versus ‐negative tumours was even more pronounced 3 days after injection (16.30±0.64% ID g−1), and was visualised by radioimmunoscintigraphy. Liver, spleen and kidney showed marked tracer uptake. In summary, trastuzumab can be efficiently radiolabelled with 111 In with high labelling yields and high stability. 111 In‐DTPA‐trastuzumab selectively binds to the human HER2 receptor both in vitro and in vivo in animals. Therefore, 111 In‐DTPA‐trastuzumab appears suitable for clinical use. British Journal of Pharmacology (2004) 143, 99–106. doi:10.1038/sj.bjp.0705915

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0705915

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 176

Metadata

Authors
Lub‐de Hooge, M. N., Kosterink, J. G. W., Perik, P. J., Nijnuis, H., Tran, L., Bart, J., Suurmeijer, A. J. H., de Jong, S., Jager, P. L., & de Vries, E. G. E.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2004-09
Volume
143
Issue
1
Pages
99-106
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1982322665
Cited by
176
References
1
FWCI
5.35
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical characterisation of 111In‐DTPA‐trastuzumab. https://app.cochat.ai/papers/10.1038/sj.bjp.0705915
The paper
Lub‐de Hooge, M. N., Kosterink, J. G. W., Perik, P. J., Nijnuis, H., Tran, L., Bart, J., Suurmeijer, A. J. H., de Jong, S., Jager, P. L., & de Vries, E. G. E. (2004). Preclinical characterisation of 111In‐DTPA‐trastuzumab. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0705915

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.